๐Ÿ‡บ๐Ÿ‡ธ USC
Health & Fitness
๐Ÿ’“

PREVENT & ASCVD Risk Calculator

10- and 30-year heart risk with the AHA PREVENT equations and the 2013 Pooled Cohort Equations

The PREVENT calculator estimates the chance of a first heart attack, stroke or heart failure over the next 10 and 30 years for adults 30 to 79, using the American Heart Association's PREVENT equations, and shows the older ASCVD risk score from the 2013 Pooled Cohort Equations next to it. In the worked example of the PREVENT supplement, a 50-year-old woman with diabetes, a treated systolic pressure of 160 mm Hg, total cholesterol of 200 mg/dL and HDL of 45 mg/dL has a 10-year total CVD risk of 14.7% (ASCVD 9.2%, heart failure 8.1%) and a 30-year risk of 53.0%.

โœ…

Last updated: November 10, 2026

Method: PREVENT base equations of Khan et al. (Circulation, 2024) with the coefficients, centering and spline terms of Supplemental Tables S12A (10-year) and S12F (30-year). The AHA's correction of October 14, 2026 changed only the optional add-on equations that include HbA1c, not the base equations used here. Pooled Cohort Equations from Table A of the 2013 ACC/AHA risk assessment guideline (Goff et al.), with the same constants as the ACC CVD Risk Estimator Plus. We reproduced the base-model worked examples of the PREVENT supplement.

Included: PREVENT 10- and 30-year risk of total cardiovascular disease, ASCVD and heart failure, the 2013 PCE 10-year ASCVD risk, current guideline categories and the model terms behind each result.

Not included: The optional PREVENT add-ons (urine albumin-to-creatinine ratio, HbA1c, zip-code social deprivation index), PREVENT-Age and percentiles, people with known cardiovascular disease, ages outside 30 to 79 and any estimate of treatment benefit. For education and clinician use; not a diagnosis or medical advice.

๐Ÿฉบ Risk factors

Sex

years

PREVENT: 30 to 79. Pooled Cohort Equations: 40 to 79. 30-year risk: 30 to 59.

Cholesterol unit

mg/dL

130 to 320 mg/dL. Fasting is not required.

mg/dL

20 to 100 mg/dL.

mm Hg

90 to 200 mm Hg. Use your usual reading, ideally an average of several.

Treatment and conditions (check all that apply)

mL/min/1.73 mยฒ

15 to 150. PREVENT uses the race-free CKD-EPI 2021 creatinine equation; our eGFR calculator uses the same one.

kg/mยฒ

18.5 to under 40, the range PREVENT was developed in; any other value gives no estimate. Leave it empty to skip heart failure risk, but only if your BMI is in that range. Need it? Use the BMI calculator.

Race (used only by the 2013 Pooled Cohort Equations)

PREVENT does not use race. "Other" uses the equations for white adults, as the 2013 guideline suggests.

๐Ÿ’“ PREVENT 10-year risk of total cardiovascular disease

14.7%
Heart attack, stroke or heart failure by age 60
10-year ASCVD
9.2%
10-year heart failure
8.1%
PCE 10-year ASCVD
6.4%
30-year total CVD
53.0%
30-year ASCVD
35.4%
30-year heart failure
39.0%

About 15 in 100 people with these risk factors would be expected to have a first heart attack, stroke or heart failure within 10 years.

๐Ÿ“‹ What current guidelines do with these numbers

PREVENT-ASCVD 10-year: 9.2%Intermediate risk

With diabetes at age 40 to 75, the 2026 guideline recommends a moderate-intensity statin whatever this estimate, aiming for a 30% to 49% LDL-C reduction and an LDL-C below 100 mg/dL; a high-intensity statin is reasonable with a 10-year estimate of 10% or more or with multiple risk factors. Discuss this with your clinician.

2026 ACC/AHA dyslipidemia guideline, for adults 30 to 79 without ASCVD whose LDL-C is 70 to 189 mg/dL. An LDL-C of 190 mg/dL or more calls for a statin regardless of the estimate.

PREVENT-ASCVD 30-year: 35.4% (10% or more)

The 2026 guideline uses 30-year risk mainly for adults 30 to 59 whose 10-year risk is low. With diabetes at age 40 to 75, the recommendation above applies whatever the 30-year estimate.

PREVENT-CVD 10-year: 14.7% (7.5% or more)

The 2025 AHA/ACC blood pressure guideline uses this number for stage 1 hypertension (130 to 139 systolic or 80 to 89 diastolic) in adults without CVD, diabetes or chronic kidney disease. At 7.5% or more, starting blood pressure medicine is recommended. Below 7.5%, medicine is recommended if the average stays at 130 systolic or 80 diastolic or higher after 3 to 6 months of lifestyle changes. Stage 2 hypertension (140/90 and up) is treated regardless of risk.

Diabetes and chronic kidney disease (for example an eGFR under 60) already count as high risk in the 2025 blood pressure guideline, which does not apply the 7.5% threshold to them. The 2026 dyslipidemia guideline recommends LDL-lowering therapy for adults 40 to 75 with diabetes or chronic kidney disease stage 3 or 4 regardless of the estimate. Review the estimate with your clinician rather than against the categories alone.

๐Ÿ•ฐ๏ธ The 2013 ASCVD risk score (Pooled Cohort Equations)

PCE 10-year hard ASCVD
6.4%
Borderline (2019 cut-offs)
PREVENT-ASCVD 10-year
9.2%
PCE to PREVENT ratio: 0.69

2019 categories for the PCE: low under 5%, borderline 5% to under 7.5%, intermediate 7.5% to under 20%, high 20% or more. The 2026 dyslipidemia guideline replaced the PCE with PREVENT-ASCVD, and the ACC no longer supports PCE-based decisions. The PCE has no term for statin use or kidney function.

๐Ÿงฎ How PREVENT reads your numbers

Derived values as in Supplemental Table S12A. Cholesterol enters in mmol/L: total 5.172, HDL 1.164 (that is 200 and 45 mg/dL).

TermValue
Age: (age - 55) / 10-0.5000
Non-HDL-C: (TC - HDL) - 3.5 mmol/L0.5083
HDL-C: (HDL - 1.3) / 0.3-0.4543
SBP under 110: (min(SBP, 110) - 110) / 200.0000
SBP 110 and up: (max(SBP, 110) - 130) / 201.5000
eGFR under 60: (min(eGFR, 60) - 60) / -150.0000
eGFR 60 and up: (max(eGFR, 60) - 90) / -150.0000
BMI under 30 (HF only): (min(BMI, 30) - 25) / 51.0000
BMI 30 and up (HF only): (max(BMI, 30) - 30) / 51.0000
Log-odds, 10-year CVD / ASCVD / HF-1.7596 / -2.2900 / -2.4347

Risk = e^x / (1 + e^x), where x is the log-odds for that outcome.

For education and for use by clinicians. This is not a diagnosis and not medical advice. The equations apply to adults without heart disease, stroke or heart failure, estimate average risk for groups of similar people, and are not meant to show how much a treatment would lower your risk. Do not start, stop or change a medicine because of this number; discuss it with a clinician. Everything is computed in your browser and nothing is stored.

PREVENT and ASCVD risk calculator: equations, worked examples and guidelines

Risk equations turn a few routine numbers into the chance of a first cardiovascular event, and US guidelines use that chance to decide on statins and, since 2017 (with PREVENT since 2025), on blood pressure medicine for stage 1 hypertension. The long-time standard was the ASCVD risk calculator built on the 2013 Pooled Cohort Equations (PCE). The 2026 ACC/AHA cholesterol guideline replaced it with the American Heart Association's PREVENT equations. This page computes both, so you can see where they agree and where they do not.

What PREVENT estimates and who it is for

PREVENT stands for Predicting Risk of cardiovascular disease EVENTs. The equations were derived from 3,281,919 adults in 25 US datasets and validated in 3,330,085 adults from 21 other datasets, 6,612,004 people aged 30 to 79 without known cardiovascular disease in all. They estimate three outcomes: total cardiovascular disease (CVD), atherosclerotic cardiovascular disease (ASCVD: heart attack, coronary death and stroke) and heart failure, each over 10 and 30 years. The equations are separate for women and men, do not use race and add kidney function (eGFR) to the classic risk factors. In external validation the C-statistic for total CVD was 0.794 in women and 0.757 in men, and the calibration slopes were 1.03 and 0.94, so predicted and observed risk lined up closely.

The PREVENT equations step by step

PREVENT is a logistic model. Each outcome has its own coefficients for women and for men, and the risk is:

x = constant + sum of (coefficient × term) Risk = ex / (1 + ex)

The terms are centered so that the constant describes a 55-year-old non-smoker without diabetes, with non-HDL cholesterol of 3.5 mmol/L, HDL of 1.3 mmol/L, a systolic pressure of 130 mm Hg, an eGFR of 90 and no medication:

  • Age: (age − 55) / 10, plus its square in the 30-year equations.
  • Non-HDL cholesterol: (total − HDL) × 0.02586 − 3.5, which converts mg/dL to mmol/L.
  • HDL cholesterol: (HDL × 0.02586 − 1.3) / 0.3.
  • Systolic pressure, split at 110 mm Hg: (min(SBP, 110) − 110) / 20 and (max(SBP, 110) − 130) / 20.
  • eGFR, split at 60: (min(eGFR, 60) − 60) / −15 and (max(eGFR, 60) − 90) / −15.
  • BMI, heart failure only, split at 30: (min(BMI, 30) − 25) / 5 and (max(BMI, 30) − 30) / 5.
  • Yes/no terms: diabetes, current smoking, blood pressure medicine and statin use.
  • Interactions: treated SBP, treated non-HDL cholesterol, and age with non-HDL, HDL, SBP, diabetes, smoking, BMI and low eGFR.

The heart failure equations leave out cholesterol and statin use, and only they use BMI. The development models use age as the time scale and account for the competing risk of dying of other causes first; the published equations reproduce them closely (R² of at least 0.99 for 10-year and 0.97 for 30-year risk) and are what the AHA's own online calculator runs.

Worked example: the calculation in the PREVENT supplement

Supplemental Table S12A works through one profile, which the calculator above loads by default: a 50-year-old woman with total cholesterol 200 mg/dL, HDL 45 mg/dL, a systolic pressure of 160 mm Hg on blood pressure medicine, diabetes, no smoking, a BMI of 35, an eGFR of 90 and no statin. Her terms are age −0.5, non-HDL 0.5083, HDL −0.4543 and SBP 1.5, with the low-SBP and both eGFR terms at 0. Each term adds to the log-odds of 10-year total CVD:

Term (value) Coefficient Contribution
Constant−3.307728−3.3077
Age (−0.5)0.7939329−0.3970
Non-HDL cholesterol (0.5083)0.03052390.0155
HDL cholesterol (−0.4543)−0.16068570.0730
SBP 110 and above (1.5)0.36007810.5401
Diabetes (1)0.86676040.8668
Blood pressure medicine (1)0.31516720.3152
Treated SBP (1.5)−0.0663612−0.0995
Age × non-HDL (−0.2542)−0.08197150.0208
Age × HDL (0.2272)0.03067690.0070
Age × SBP (−0.75)−0.09463480.0710
Age × diabetes (−0.5)−0.270570.1353
Log-odds x−1.7596

Her risk is e−1.7596 / (1 + e−1.7596) = 0.1468, a 10-year total CVD risk of 14.7%. The ASCVD and heart failure equations give 9.2% and 8.1%, and the 30-year equations give 53.0%, 35.4% and 39.0%. A man with the same numbers comes out at 16.3%, 10.2% and 10.6% over 10 years and 51.4%, 34.9% and 42.4% over 30 years. All twelve results match the values printed in the supplement.

Second example: the 50-year-old woman in the PREVENT paper

The paper's results section describes a 50-year-old woman with total cholesterol 240 mg/dL, HDL 55 mg/dL, a treated systolic pressure of 160 mm Hg, no diabetes, no smoking, a BMI of 35 and an eGFR of 90. The calculator gives 10-year risks of 5.4% (total CVD), 3.6% (ASCVD) and 2.5% (heart failure), as the paper reports, and 9.3%, 6.0% and 4.7% if she smoked, again as published. Her 30-year risks come out at 30.7%, 19.9% and 18.5%. The paper rounds to whole percent and prints 31%, 20% and 19%; the heart failure figure is the one that does not match, because the published equation gives 18.475%, which rounds to 18%. With smoking, the equations give 39.8%, 25.9% and 26.1%, in line with the paper's 40%, 26% and 26%. With an eGFR of 45 instead of 90, her 10-year total CVD risk is 11.1%, a bigger jump than smoking causes.

The ASCVD risk calculator: the 2013 Pooled Cohort Equations

The ASCVD risk calculator most clinicians know comes from the 2013 ACC/AHA guideline on the assessment of cardiovascular risk. Its equations were built from NHLBI-sponsored cohort studies (ARIC, the Cardiovascular Health Study and CARDIA) combined with the Framingham original and offspring cohorts: 11,240 white women, 9,098 white men, 2,641 African American women and 1,647 African American men aged 40 to 79. They predict a first hard ASCVD event, meaning nonfatal heart attack, coronary death or fatal or nonfatal stroke, within 10 years, with a separate equation for each sex and race group:

Risk = 1 − S10 ^ exp(individual sum − group mean)

The individual sum uses the natural logarithms of age, total cholesterol, HDL and treated or untreated systolic pressure, age interactions and yes/no terms for smoking and diabetes. Baseline survival S10 is 0.96652 for white women, 0.95334 for African American women, 0.91436 for white men and 0.89536 for African American men, the constants of the ACC's online estimator (Table A prints them rounded to four decimals). A lipid treatment term was tested and dropped, so the PCE ignore statin use; eGFR and BMI are not used either. For other groups, the guideline suggests the equations for white adults and warns that they may overestimate risk for Hispanic and Asian Americans.

Table A of the guideline works one example: a 55-year-old with total cholesterol 213 mg/dL, HDL 50 mg/dL, an untreated systolic pressure of 120 mm Hg, no smoking and no diabetes. The calculator returns 2.1% for a white woman, 3.0% for an African American woman, 5.4% for a white man and 6.1% for an African American man. Table A prints 5.3% for the white man because it cuts his intermediate sum off at 60.69 (exact: 60.6995); computed without that shortcut, as in the ACC's online estimator, the result is 5.4%.

PREVENT vs ASCVD: how the two models differ

Feature PREVENT (2023) Pooled Cohort Equations (2013)
Ages30 to 7940 to 79
OutcomesTotal CVD, ASCVD, heart failureHard ASCVD only
Time horizon10 and 30 years10 years
RaceNot usedWhite or African American equations
Kidney function, statin use, BMIeGFR in all equations, statin use for CVD and ASCVD, BMI for heart failureNone of them
Data6.6 million adults, 46 datasets, baselines 1992 to 201724,626 adults from ARIC, CHS, CARDIA and Framingham
Calibration in PREVENT's validation dataSlope 1.03 (women) and 0.94 (men) for total CVDSlope 0.54 (women) and 0.50 (men) for ASCVD: risk overestimated by about half
Main statin threshold5% 10-year ASCVD risk (2026 guideline)7.5% (2013 and 2018 guidelines)

The gap matters in practice. In the PREVENT study, people whose PCE estimate was 7.5%, the old statin threshold, had a median PREVENT-ASCVD estimate of 4.9% if female and 3.7% if male. A PREVENT number therefore has to be read against PREVENT thresholds, never against the PCE cut-offs.

Same people, two scores

These results come from the calculator above for a few typical profiles: no smoking unless stated, no statin, and the white-race equations for the PCE. PREVENT is lower in most of them but not in all; with diabetes it can come out higher.

Profile PREVENT CVD PREVENT ASCVD PCE ASCVD
Woman, 45: TC 200, HDL 55, SBP 125 untreated, eGFR 951.4%0.9%0.8%
Man, 55: TC 220, HDL 45, SBP 138 untreated, eGFR 855.9%4.1%7.8%
The same man, smoking8.8%6.0%14.3%
Man, 65: TC 200, HDL 42, SBP 145 treated, eGFR 7014.8%9.4%19.9%
Woman, 70: TC 220, HDL 60, SBP 140 treated, eGFR 6514.1%8.1%15.1%
Man, 75: TC 190, HDL 45, SBP 142 treated, eGFR 6224.8%15.2%33.7%
Woman, 50, diabetes: TC 200, HDL 45, SBP 160 treated, eGFR 9014.7%9.2%6.4%

The 55-year-old man shows the reclassification: his PCE estimate of 7.8% was intermediate under the 2019 guideline, where a statin was recommended after a risk discussion, while his PREVENT-ASCVD estimate of 4.1% is borderline under the 2026 guideline, where a statin is reasonable. As a smoker he would be intermediate under both.

What the numbers mean under current guidelines

For adults 30 to 79 without ASCVD whose LDL cholesterol is 70 to 189 mg/dL, the 2026 ACC/AHA guideline on dyslipidemia sorts 10-year PREVENT-ASCVD risk into the four groups in the table below. Adults 40 to 75 with diabetes or chronic kidney disease stage 3 or 4 are an exception: the guideline recommends LDL-lowering therapy for them regardless of the estimate. With diabetes, that means a moderate-intensity statin, or a high-intensity statin when the estimate is 10% or more or several risk factors are present. For adults over 75, the guideline's section on older adults is more cautious than the table: with a life expectancy of at least 2.5 years, starting a moderate-intensity statin may be reasonable after weighing benefits and risks, including frailty, other illnesses and medicines; with diabetes, this replaces the table at that age.

Category 10-year PREVENT-ASCVD Guideline approach
LowUnder 3%Healthy lifestyle, unless diabetes or chronic kidney disease stage 3 or 4 at ages 40 to 75 calls for LDL-lowering therapy; for ages 30 to 59, also check 30-year risk and LDL-C
Borderline3% to under 5%Statin reasonable after a clinician-patient discussion
Intermediate5% to under 10%At least a moderate-intensity statin; LDL-C 30% to 49% lower, goal under 100 mg/dL
High10% or moreHigh-intensity statin; LDL-C at least 50% lower, goal under 70 mg/dL

An LDL-C of 190 mg/dL or higher calls for maximally tolerated statin therapy whatever the estimate. Blood pressure decisions use 10-year PREVENT-CVD instead: the 2025 AHA/ACC high blood pressure guideline applies it to stage 1 hypertension (130 to 139 systolic or 80 to 89 diastolic) in adults without CVD, diabetes or chronic kidney disease. At 7.5% or more, medication is recommended; below that, it follows if pressure stays at 130 systolic or 80 diastolic or higher after 3 to 6 months of lifestyle change. A 62-year-old man with an untreated systolic pressure of 134 mm Hg, total cholesterol 210 mg/dL, HDL 45 mg/dL and an eGFR of 85 has a PREVENT-CVD risk of 8.6%; at 58 it is 6.6%.

The older PCE categories were low under 5%, borderline 5% to under 7.5%, intermediate 7.5% to under 20% and high at 20% or more (2018 cholesterol and 2019 prevention guidelines). They belong to the PCE and should not be applied to PREVENT numbers. The ACC's online estimator now states that the 10-year risk from the Pooled Cohort Equations is no longer supported by ACC clinical policy or guidelines.

30-year risk for adults 30 to 59

Ten-year risk stays low for most adults under 45, even with high cholesterol, so the 30-year estimate fills the gap. The ACC's CVD Risk Estimator Plus reports it for ages 30 to 59, as does this calculator. The 2026 guideline uses 30-year ASCVD risk for adults 30 to 59 whose 10-year risk is under 3%: a moderate-intensity statin is reasonable if 30-year risk is 10% or more or LDL-C is 160 to 189 mg/dL; otherwise lifestyle counseling is the focus. From age 40, diabetes or chronic kidney disease stage 3 or 4 changes this: the guideline then recommends LDL-lowering therapy regardless of either estimate. A 38-year-old man with total cholesterol 240 mg/dL, HDL 40 mg/dL, a systolic pressure of 128 mm Hg and an eGFR of 100 has a 10-year ASCVD risk of 1.4% and a 30-year risk of 9.5%. As a smoker, his 30-year figure is 14.1%, past the 10% mark, while his 10-year risk is only 2.4%. No guideline has set a threshold for 30-year total CVD.

How to use this calculator

Enter sex and age, then total and HDL cholesterol from a recent lipid panel (fasting is not required). The mmol/L switch converts the numbers without changing the result. Use your usual systolic pressure, ideally an average of several readings, and tick blood pressure medicine if you take any, because the equations treat a treated reading differently. eGFR is on most basic metabolic panels; PREVENT uses the race-free CKD-EPI 2021 creatinine equation, as does our eGFR calculator. BMI is needed only for heart failure, race only for the PCE. You can leave BMI empty if it is 18.5 to under 40; heart failure risk is then not shown. A value outside the allowed ranges, including a BMI under 18.5 or of 40 or more, produces a message instead of a number, as in the AHA calculator.

Limitations and who should not use it

PREVENT is for primary prevention in adults 30 to 79 without a history of heart attack, stroke, other ASCVD or heart failure; people with those conditions follow separate recommendations. The equations come from US data, and the AHA advises caution elsewhere. People with a BMI under 18.5 or of 40 or more were excluded from development, and a supplemental analysis found modest underestimation of risk above a BMI of 40; the calculator therefore gives no estimate for a BMI under 18.5 or of 40 or more. The estimates describe groups of similar people, not certainties for one person, and changing inputs to mimic treatment does not show how much a medicine would lower risk. The optional add-on equations with urine albumin, HbA1c or zip-code deprivation are not included. The PCE share these limits and add their own: they start at age 40, use race and overestimate risk today.

Key terms

  • ASCVD: atherosclerotic cardiovascular disease; in PREVENT, heart attack, coronary death and stroke.
  • Total CVD: ASCVD plus heart failure. It is less than the sum of the two because some people have both.
  • Non-HDL cholesterol: total cholesterol minus HDL, the cholesterol carried by particles that build plaque.
  • eGFR: estimated glomerular filtration rate, kidney function calculated from blood creatinine.
  • Calibration slope: how closely predicted risk tracks observed risk; 1.0 is a perfect match and values well below 1 mean overestimation.

Sources

  • Khan SS, Matsushita K, Sang Y, et al. (2024). Development and Validation of the American Heart Association's PREVENT Equations. Circulation 149:430-449, with Supplemental Tables S12A and S12F. Circulation · PubMed · Full text and supplement (PubMed Central)
  • Khan SS, Coresh J, Pencina MJ, et al. (2023). Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement From the American Heart Association. Circulation 148:1982-2004. Circulation
  • American Heart Association. PREVENT Online Calculator, PREVENT FAQs and the PREVENT Equations Update FAQ of October 14, 2026. professional.heart.org · Update FAQ (PDF)
  • Goff DC Jr, Lloyd-Jones DM, et al. (2014). 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk, Table A. Circulation 129(25 Suppl 2):S49-S73. Circulation · PubMed · Full text (PubMed Central)
  • National Heart, Lung, and Blood Institute (2013). Assessing Cardiovascular Risk: Systematic Evidence Review from the Risk Assessment Work Group. nhlbi.nih.gov
  • Blumenthal RS, Morris PB, Gaudino M, et al. (2026). 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Circulation 153:e1154-e1276. Circulation · PubMed
  • Jones DW, Ferdinand KC, Taler SJ, et al. (2025). 2025 AHA/ACC Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults. Circulation 152:e114-e218. Circulation · PubMed
  • Grundy SM, Stone NJ, Bailey AL, et al. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation 139:e1082-e1143. Circulation · PubMed · Author manuscript (executive summary)
  • Arnett DK, Blumenthal RS, et al. (2019). 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation 140:e596-e646. Full text (PubMed Central)
  • KDIGO CKD Work Group (2024). KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International 105(4S):S117-S314. PubMed
  • American College of Cardiology. CVD Risk Estimator Plus (PREVENT and Pooled Cohort modes). tools.acc.org

โš ๏ธ Common mistakes & edge cases

Using it after a heart attack or stroke

Both models are for people without known cardiovascular disease. With ASCVD or heart failure, risk is already high and the estimate does not apply.

Reading PREVENT against the old 7.5% threshold

7.5% was the PCE statin cut-off. PREVENT-ASCVD uses 3%, 5% and 10%. The 7.5% figure survives only for PREVENT-CVD in the blood pressure decision.

Mixing up cholesterol units

A total cholesterol of 5.2 is in mmol/L and 200 is in mg/dL. The calculator rejects a value outside the range of the selected unit instead of guessing.

Entering one high blood pressure reading

A single office reading can mislead. Use the average of several readings.

Using an older, race-based eGFR

PREVENT was built with the 2021 CKD-EPI equation, which has no race term. Older reports may list a race-adjusted value; recalculate it with our eGFR calculator.

Changing inputs to estimate a treatment's benefit

The AHA notes that the equations are not meant to show how much a treatment lowers risk. Ticking the statin box in the paper's example even moves 10-year total CVD from 5.4% to 5.5%: the equations describe people who take a statin, not the effect of starting one.

Note: This calculator is for education and for use by clinicians. It does not diagnose disease and does not replace a medical evaluation. Never start, stop or change a medicine because of this result; discuss it with a clinician.

❓ Frequently asked questions

What is the PREVENT calculator?

The PREVENT calculator uses the American Heart Association's PREVENT equations (2023) to estimate the 10- and 30-year risk of a first heart attack, stroke or heart failure in adults 30 to 79 without known cardiovascular disease. Inputs are age, sex, total and HDL cholesterol, systolic blood pressure, blood pressure and statin medicine, diabetes, smoking and kidney function (eGFR), plus BMI for heart failure. The equations come from more than 6.6 million US adults and do not use race.

What is a good PREVENT score?

Lower is better, and the 2026 ACC/AHA cholesterol guideline sets the bands for 10-year PREVENT-ASCVD risk: under 3% is low, 3% to under 5% borderline, 5% to under 10% intermediate and 10% or more high. A 45-year-old woman with total cholesterol 200 mg/dL, HDL 55 mg/dL, a systolic pressure of 125 mm Hg, normal kidney function and no other risk factors has a 10-year PREVENT-ASCVD risk of about 0.9%. For adults 30 to 59, guidelines also look at whether 30-year ASCVD risk stays under 10%.

What is the difference between PREVENT and the ASCVD risk calculator?

The ASCVD risk calculator uses the 2013 Pooled Cohort Equations: ages 40 to 79, separate equations for white and African American adults, and 10-year risk of heart attack or stroke only. PREVENT covers ages 30 to 79, does not use race, adds kidney function and statin use, also estimates heart failure and total cardiovascular disease, and adds a 30-year horizon. It rests on far larger, more recent data and is better calibrated today.

Why is my PREVENT risk lower than my ASCVD risk score?

In recent data the Pooled Cohort Equations overestimate risk: their calibration slopes were 0.54 in women and 0.50 in men, against about 1.0 for PREVENT. People with a PCE estimate of 7.5% had a median PREVENT-ASCVD estimate of 4.9% if female and 3.7% if male. Compare a PREVENT number with the PREVENT thresholds of 3%, 5% and 10%, not with the old 7.5% cut-off. PREVENT is not always lower: diabetes or reduced kidney function can put it above the PCE.

Is the ASCVD risk calculator still used?

Less and less. The 2026 ACC/AHA dyslipidemia guideline replaced the Pooled Cohort Equations with PREVENT-ASCVD for primary prevention, and the ACC's online estimator states that the PCE 10-year risk is no longer supported by ACC clinical policy or guidelines. The PCE remain in older records and research, so this page shows both side by side.

What PREVENT score means I should take a statin?

Under the 2026 guideline, for adults 30 to 79 without ASCVD and with an LDL cholesterol of 70 to 189 mg/dL, a statin is recommended at a 10-year PREVENT-ASCVD risk of 5% or more and is reasonable at 3% to under 5% after a discussion with a clinician. Below 3%, adults 30 to 59 can still qualify if their 30-year risk is 10% or more or their LDL-C is 160 to 189 mg/dL. An LDL-C of 190 mg/dL or higher calls for a statin regardless. Adults 40 to 75 with diabetes or chronic kidney disease stage 3 or 4 are an exception: the guideline recommends LDL-lowering therapy for them regardless of the estimate. Over 75, the guideline is more cautious: with a life expectancy of at least 2.5 years, starting a moderate-intensity statin may be reasonable after weighing benefits and risks. Decide together with your clinician.

Why does PREVENT ask for kidney function (eGFR)?

Reduced kidney function raises the risk of heart attack, stroke and especially heart failure, and eGFR is on most routine blood panels. The effect can be large: for the 50-year-old woman described in the PREVENT paper, an eGFR of 45 instead of 90 raises her 10-year total CVD risk from 5.4% to 11.1%. Use an eGFR from the race-free CKD-EPI 2021 equation, the one PREVENT was built with.

Why is there no 30-year risk after age 59?

The ACC's CVD Risk Estimator Plus reports 30-year PREVENT estimates only for ages 30 to 59, and this calculator follows it. The 2026 cholesterol guideline uses 30-year risk in that age group, for people whose 10-year risk is still low. From 60 on, guidelines act on the 10-year estimate.

Does PREVENT use race?

No. The developers treated race as a social construct rather than a biological predictor and checked that the equations predict well across groups: calibration slopes for total CVD were 1.11 in Black, 0.87 in Asian, 1.01 in non-Hispanic white and 0.94 in Hispanic adults, where 1.0 is a perfect match. The 2013 Pooled Cohort Equations do use race, with separate equations for white and African American adults.

Can I use the PREVENT calculator after a heart attack or stroke?

No. PREVENT and the Pooled Cohort Equations are for people without known cardiovascular disease. After a heart attack or stroke, risk is already high and treatment follows secondary prevention recommendations, which in the 2026 guideline include an LDL-C goal below 55 mg/dL for patients at very high risk. Heart failure is not ASCVD, so a heart failure diagnosis is managed under the heart failure guideline instead.

๐Ÿ’ก Good to know

Total CVD is not ASCVD plus heart failure

Some people have both events, so total CVD risk is lower than the sum. In the worked example, ASCVD is 9.2% and heart failure 8.1%, but total CVD is 14.7%.

A new score came with new thresholds

Moving from the PCE to PREVENT lowers many estimates by a third to a half, and the cut-offs came down with them: 5% replaced 7.5% as the point where a statin is recommended.

The October 2026 correction does not change these results

On October 14, 2026 the AHA corrected the HbA1c coefficient in the optional PREVENT add-on equations. The base equations used here were not affected.

Related Calculators